PMS Registry
Company Name
Pfizer Inc.
Protocol Number
Title of Study
An Observational Study of Xeljanz® (tofacitinib citrate) and Biologic Rheumatoid Arthritis Treatments to Characterize their General Treatment Patterns, Effectiveness and Safety in a Real-World Taiwanese Population
Primary Objective
The main objective of this multicenter, prospective, observational comparative effectiveness study in Taiwan is to understand general treatment patterns, effectiveness, and safety of tofacitinib compared to TNFi in a non-restricted population of RA patients in the real-world setting.
Number of Sites
Period of Study
From:June 2016 to:August 2021
Number of Patients
IRB Approval Date
Kaohsiung Medical University Hospital Institutional Review Board; Approval Date: April 29, 2016
Publication Plan / Date
August 2022